Skip to main content
SpringerPlus

Table 3 Patients’ willingness-to-pay per month for one level change of each attribute (US$)

From: Patients’ preferences and willingness-to-pay for postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer treatments after failure of standard treatments

 

Progression free survival

Anemia

Pneumonitis

Average willingness-to-pay

151.6

−69.8

−278.3

95 % confidence interval

121.1–182.2

(−131.6)–(−8.2)

(−374.8)–(−183.9)

Back to article page